Source comparison
Tesamorelin + Ipamorelin Blend: Clinical Comparison
Tesamorelin monotherapy GHRH analog. Pituitary GH release 15.2% (26 weeks) Neutral to slight improvement Minimal Effective for VAT but limited lean mass preservation Ipamorelin monotherapy Selective ghrelin agonist. Pulsatile GH 8–10% (24 weeks) Neutral None G
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy
- GHRH analog. Pituitary GH release
- 15.2% (26 weeks)
- Neutral to slight improvement
- Minimal
- Effective for VAT but limited lean mass preservation
- Ipamorelin monotherapy
- Selective ghrelin agonist. Pulsatile GH
- 8–10% (24 weeks)
- Neutral
- None
- Good safety profile but slower VAT response
- Exogenous GH
- Direct GH receptor activation
- 12–14% (24 weeks)
- Worsens insulin resistance
- Fast results but metabolic trade-offs limit long-term use
- Tesamorelin + Ipamorelin blend
- Dual-pathway GH stimulation
- 18–22% (26 weeks)
- Slight improvement due to VAT loss
- Minimal to none
- Best balance of efficacy, safety, and insulin preservation
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin agonist
- 10–14% (24 weeks)
- Similar mechanism but longer half-life creates less pulsatile GH pattern